ASP 1929

Drug Profile

ASP 1929

Alternative Names: ASP-1929; RM-1929

Latest Information Update: 04 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aspyrian Therapeutics
  • Developer Rakuten Aspyrian
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Head and neck cancer

Most Recent Events

  • 23 Aug 2018 Aspyrian Therapeutics is now called Rakuten Aspyrian
  • 16 Jan 2018 Phase-I clinical trials in Head and neck cancer (Recurrent) in Japan (IV)
  • 16 Jan 2018 RM 1929 receives Fast Track designation for Head and neck cancer [IV,Infusion] (Recurrent, Second-line therapy or greater) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top